Abstract Search

ey0015.13-16 | Advances in the Diagnosis and Management of Congenital Hypothyroidism | ESPEYB15

13.16 Incidence of congenital hypothyroidism in China: data from the national newborn screening program, 2013-2015

K Deng , C He , J Zhu , J Liang , X Li , X Xie , P Yu , N Li , Q Li , Y Wang

To read the full abstract: J Pediatr Endocrinol Metab 2018; 31(6):601-608This article summarizes the findings of likely the largest program of neonatal congenital hypothyroidism (CH) screening in the world. This is a truly impressive effort. The overall incidence of CH was 1/2421, in line with other reports that also observed a relatively high incidence of CH in neonates born in Asia. However, a...

0 shares

ey0015.11-12 | Hungry fat cells | ESPEYB15

11.12 Asprosin is a centrally acting orexigenic hormone

C Duerrschmid , Y He , C Wang , C Li , JC Bournat , C Romere , PK Saha , ME Lee , KJ Phillips , M Jain , P Jia , Z Zhao , M Farias , Q Wu , DM Milewicz , VR Sutton , DD Moore , NF Butte , MJ Krashes , Y Xu , AR Chopra

To read the full abstract: Nat Med. 2017 Dec; 23(12): 1444–1453This study highlights the importance of asprosin in the regulation of appetite. This peptide hormone was first described by Romere et al. in 2016 (1), who reported 2 patients with neonatal progeroid syndrome (NPS) due to truncating heterozygous mutations in the fibrillin-gene (FBN1). The FBN1 gene encodes profibrillin wh...

0 shares

ESPE Yearbook of Paediatric Endocrinology

13.16 Incidence of congenital hypothyroidism in China: data from the national newborn screening program, 2013-2015

11.12 Asprosin is a centrally acting orexigenic hormone

BiosciAbstracts